Elevated Levels of T-helper 17-associated Cytokines in Diabetes Type I Patients: Indicators for Following the Course of Disease

Baharlou, Rasoul; Ahmadi-Vasmehjani, Abbas; Davami, Mohammad Hassan; Faraji, Fatemeh; Atashzar, Mohammd Reza; Karimipour, Firoozeh; Sadeghi, Alireza; Asadi, Mohammad-Ali; Khoubyari, Mahshid

doi:10.1080/08820139.2016.1197243

Cited by 35 publications

(21 citation statements)

References 35 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In addition, in long term type 1 diabetic mice that still present residual pancreatic β-cell function, the number of circulating IL-17A+ cells was higher than the number of Tregs, CD4+ T cells, and CD8+ T cells [35]. Moreover, serum levels of several Th17 related cytokines, including IL-17A and IL-21, were higher in diabetic patients than in controls [36,37]. In type 2 diabetic patients, there is a low grade systemic inflammation associated with altered T cell populations, including reduced overall T cells, Th17, IL-21R+, Tregs, and TLR4+ T cells, while monocytes show enhanced TLR4 expression; however, the Treg/Th17 ratio was not explored [38].…”

Section: Th17 Immune Cells and Il-17a In Human Diabetes And Diabetic mentioning

confidence: 93%

Could IL-17A Be a Novel Therapeutic Target in Diabetic Nephropathy?

Lavoz

Rayego‐Mateos

Orejudo

et al. 2020

JCM

View full text Add to dashboard Cite

Chronic kidney disease has become a major medical issue in recent years due to its high prevalence worldwide, its association with premature mortality, and its social and economic implications. A number of patients gradually progress to end-stage renal disease (ESRD), requiring then dialysis and kidney transplantation. Currently, approximately 40% of patients with diabetes develop kidney disease, making it the most prevalent cause of ESRD. Thus, more effective therapies for diabetic nephropathy are needed. In preclinical studies of diabetes, anti-inflammatory therapeutic strategies have been used to protect the kidneys. Recent evidence supports that immune cells play an active role in the pathogenesis of diabetic nephropathy. Th17 immune cells and their effector cytokine IL-17A have recently emerged as promising targets in several clinical conditions, including renal diseases. Here, we review current knowledge regarding the involvement of Th17/IL-17A in the genesis of diabetic renal injury, as well as the rationale behind targeting IL-17A as an additional therapy in patients with diabetic nephropathy.

show abstract

Section: Th17 Immune Cells and Il-17a In Human Diabetes And Diabetic mentioning

confidence: 93%

Could IL-17A Be a Novel Therapeutic Target in Diabetic Nephropathy?

Lavoz

Rayego‐Mateos

Orejudo

et al. 2020

JCM

View full text Add to dashboard Cite

show abstract

“…However, consistent with previous studies, the role of IL-17 in murine skin lesions is less clear and is likely overshadowed by other cytokines (Swindell et al, 2017). In humans, the role of IL-17 in type 1 (autoimmune) diabetes is already under investigation (Baharlou et al, 2016), and it has been suggested that antieIL-17A mAb may have a role in the prevention of diabetic end-organ damage (Mohamed et al, 2016;Qiu et al, 2017).…”

Section: Closing Remarksmentioning

confidence: 66%

IL-17 May Be a Key Cytokine Linking Psoriasis and Hyperglycemia

Gardner

Grantham

Reynolds

2019

Journal of Investigative Dermatology

View full text Add to dashboard Cite

show abstract

“…Human Ad-MSCs possess particular properties that make them appropriate to be used as a regenerative and immunomodulatory agent [25]. In RA, as an auto-inflammatory disease, pro-inflammatory cytokines such as TNF-α, IL-6, IL-1 and IL-17 play dominant pathological roles, and also Th1 and Th17 cell subsets are well known to mediate inflammation in the pathogenesis of the disease [11,12,26]. Therefore, finding new agents which can affect cytokine production by these cell lineages may lead to a promising treatment for RA.…”

Section: Discussionmentioning

confidence: 99%